Drug Profile
Exenatide long-acting - Delpor
Alternative Names: DLP-414Latest Information Update: 15 Sep 2023
Price :
$50
*
At a glance
- Originator Delpor
- Class Antihyperglycaemics; Obesity therapies; Peptides; Venoms
- Mechanism of Action Glucagon like peptide 1 receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Type 2 diabetes mellitus
Most Recent Events
- 15 Sep 2023 Discontinued - Preclinical for Type 2 diabetes mellitus in USA (SC)
- 28 Sep 2020 No recent reports of development identified for preclinical development in Type-2-diabetes-mellitus in USA (SC, Implant)
- 14 Jun 2017 Delpor receives SBIR grant from National Institute of Diabetes and Digestive and Kidney Diseases for Exenatide long-acting development in Type-2 diabetes mellitus